Literature DB >> 19711120

Management of non-motor complications in Parkinson's disease.

Ken-ichi Fujimoto1.   

Abstract

This paper summarizes the methods we devised for the treatment of psychosis, orthostatic hypotension, and mood disorders among the various non-motor complications of Parkinson's disease. Psychosis may not manifest when a patient believes in his/her delusions. If left untreated over a prolonged period, however, the delusions progress to paranoia that is very difficult to cure. Accordingly, enquiries should be made during routine examinations to detect the presence of psychosis and facilitate early discovery. Atypical antipsychotics are used when psychosis does not improve after reducing the doses of antiparkinson drugs. We achieved favorable results by using mianserin hydrochloride prior to this step, with efficacy being observed for hallucinations and mild delusions that often manifested at night. This drug does not act as a dopamine receptor blocker, so it has the advantage of not aggravating motor symptoms. With this therapy, it is also possible to improve motor symptoms without inducing psychosis by reducing the doses of antiparkinson drugs and locally stimulating the motor loop by deep brain stimulation of the subthalamic nucleus. We previously introduced leg-holding exercises for the treatment of orthostatic hypotension, through which blood pooled in the veins is returned to the systemic circulation by holding the knees. This can be done easily and is free of adverse reactions. Mood disorders are difficult to cope with in patients with Parkinson's disease, but may be treated by selecting an appropriate dopamine agonist while giving consideration to affinity for the dopamine D3 receptor. However, treatment becomes complicated when the dopamine receptor is overstimulated. Here we report on cases of successfully treated pathological gambling and dopamine dysregulation syndrome, which are considered difficult to manage. The solution may differ depending on a patient's environment, and it is not easy to prescribe therapy based on evidence-based medicine. The best therapy should be selected by maintaining communication with the patient and developing a relationship built on trust.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711120     DOI: 10.1007/s00415-009-5245-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

Review 1.  Intrinsic and extrinsic psychosis in Parkinson's disease.

Authors:  E C Wolters
Journal:  J Neurol       Date:  2001-09       Impact factor: 4.849

2.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

3.  FDA warns antipsychotic drugs may be risky for elderly.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

4.  Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.

Authors:  Matthias R Lemke; H Michael Brecht; Juergen Koester; Heinz Reichmann
Journal:  J Neurol Sci       Date:  2006-06-30       Impact factor: 3.181

5.  Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.

Authors:  Paolo Barone; Leonardo Scarzella; Roberto Marconi; Angelo Antonini; Letterio Morgante; Fulvio Bracco; Mario Zappia; Bruno Musch
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

6.  Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

Authors:  Bernard Ravina; Karen Marder; Hubert H Fernandez; Joseph H Friedman; William McDonald; Diane Murphy; Dag Aarsland; Debra Babcock; Jefferey Cummings; Jean Endicott; Stewart Factor; Wendy Galpern; Andrew Lees; Laura Marsh; Mark Stacy; Katrina Gwinn-Hardy; Valerie Voon; Christopher Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

Review 7.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

Review 8.  Impulse-control disorders in Parkinson's disease.

Authors:  Joseph M Ferrara; Mark Stacy
Journal:  CNS Spectr       Date:  2008-08       Impact factor: 3.790

Review 9.  Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

Authors:  David S Goldstein
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

10.  Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs.

Authors:  K Ikeguchi; A Kuroda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

View more
  4 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 2.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 3.  Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.

Authors:  Seyed-Mohammad Fereshtehnejad; Johan Lökk
Journal:  Parkinsons Dis       Date:  2014-02-02

Review 4.  Evidence Supports PA Prescription for Parkinson's Disease: Motor Symptoms and Non-Motor Features: A Scoping Review.

Authors:  Yi-Chen Cheng; Chun-Hsien Su
Journal:  Int J Environ Res Public Health       Date:  2020-04-22       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.